Objective To explore the application effect of Sacubitril Valsartan in elderly patients with chronic heart failure(CHF).Methods A total of 83 elderly CHF patients admitted to the Department of General Practice and Geriatric of Shaodong People's Hospital from January 2021 to April 2022 were selected as the study subjects,and they were divided into Group A(41 cases)and Group B(42 cases)according to the random number table method.Patients in Group A were treated with Candesartan,while patients in Group B were treated with Sacubitril Valsartan.The total effective rate of treatment,ventricular remodeling indicators,N-terminal pro-brain-type natriuretic peptide (NT-proBNP) levels and incidence of adverse reactions were compared between the two groups of patients.Results The total effective rate of treatment in Group B was higher than that in Group A,the difference was statistically significant (P＜0.05).After treatment,the interventricular septal thickness(IVST)and left ventricular posterior wall thickness(LVPWT)of the two groups were lower than those before treatment,the left ventricular mass index(LVMI)was higher than that before treatment,the IVST and LVPWT of patients in Group B after treatment were lower than those in Group A,the LVMI was higher than that in Group A,the differences were statistically significant (P＜0.05).The levels of NT-proBNP in both groups of patients after treatment was lower than that before treatment,the NT-proBNP levels of patients in G roup B after treatment was lower than that in Group A,the differences were statistically significant (P＜0.05).The total incidence of adverse reactions in Group B patients was lower than that in Group A,the difference was statistically significant (P＜0.05).Conclusion The clinical effect of Sacubitril Valsartan in the treatment of elderly CHF is significant,which can effectively improve ventricular remodeling indicators in patients,reduce the occurrence of adverse reactions and have high safety.